Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity.

Published

Journal Article

There is no satisfactory therapeutic intervention for peanut allergy, which accounts for most life-threatening food allergic reactions. Since IL-12 has been found to inhibit allergic airway responses in a mouse model of asthma and to cure Th2 cytokine-mediated murine schistosomiasis, we hypothesized that IL-12 treatment might also inhibit peanut allergic reactions. Consequently, we investigated the effects of oral IL-12 treatment in a murine model of peanut allergy and found that oral administration of liposome encapsulated rIL-12 could both prevent and reverse peanut hypersensitivity and could reduce histamine release, peanut-specific serum IgE and IgG1, and fecal IgA levels. Oral IL-12 treatment also increased IFN-gamma but did not decrease IL-4 or IL-5 levels. We conclude that oral rIL-12 treatment has therapeutic as well as preventive effects on peanut allergy, which are associated with increased IFN-gamma production.

Full Text

Cited Authors

  • Lee, SY; Huang, CK; Zhang, TF; Schofield, BH; Burks, AW; Bannon, GA; Sampson, HA; Li, XM

Published Date

  • November 2001

Published In

Volume / Issue

  • 101 / 2

Start / End Page

  • 220 - 228

PubMed ID

  • 11683581

Pubmed Central ID

  • 11683581

Electronic International Standard Serial Number (EISSN)

  • 1521-7035

International Standard Serial Number (ISSN)

  • 1521-6616

Digital Object Identifier (DOI)

  • 10.1006/clim.2001.5122

Language

  • eng